Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Haematopoietic Cell Transplantation for Myelodysplasia or Acute Leukaemia in Remission

Trial Profile

Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Haematopoietic Cell Transplantation for Myelodysplasia or Acute Leukaemia in Remission

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Clofarabine (Primary) ; Melphalan; Sirolimus; Tacrolimus; Tacrolimus
  • Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 22 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 28 Jan 2014 Planned initiation date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top